Active Lawsuits Legal News Our Mission Free Case Review
Health Risk Depo-Provera May 8, 2026

Depo-Provera and Teenage Girls: Why Starting Young Dramatically Increases Brain Tumor Risk

She was 16 years old when her doctor first recommended Depo-Provera. She trusted that recommendation for fifteen years. By the time she was 31, she had a meningioma — and researchers now understand that the age she started may have made all the difference.

5.6x
Elevated meningioma risk in long-term high-dose progestin users
15+
Years of use common in women who started as teens
Risk increases linearly with cumulative dose
$0
Cost of free legal consultation
Depo-Provera prescribed to teenage girls resulting in elevated meningioma brain tumor risk from years of cumulative hormonal exposure starting in adolescence

Fifteen Years of Injections — Starting at Sixteen

Ashley was prescribed Depo-Provera at 16 to manage severe endometriosis pain. Her mother was relieved — four injections per year, no daily pill, no hormonal mood swings from the alternatives they'd tried. The gynecologist called it "one of the most reliable options." No one called it a risk.

By her late twenties, the headaches started. Persistent, pressure-like, nothing that ibuprofen could touch. Her GP attributed it to stress. Her optometrist noticed a subtle change in her peripheral vision. An MRI, ordered almost as an afterthought, revealed a meningioma — a slow-growing tumor at the base of her skull that required surgery.

She is 31 now, recovered from surgery, and part of a growing cohort of young women who researchers believe face disproportionate risk from Depo-Provera — precisely because they started young.

"Nobody told my mom or me that there was any connection between this shot and brain tumors. I was sixteen. They just said it would help my periods. I kept taking it for fifteen years because I had no reason not to. Now I feel like the decision was made for me — without all the information."

— Composite account reflecting testimony patterns from young Depo-Provera meningioma plaintiffs, 2024–2026

Why Younger First Use Means Higher Lifetime Risk

The biology here is straightforward, and the research is consistent: meningioma risk from Depo-Provera is tied to cumulative MPA exposure — the total dose of medroxyprogesterone acetate absorbed over time. A woman who starts at 16 and uses Depo-Provera for 12 years accumulates nearly three times the total hormonal exposure of a woman who starts at 30 and uses it for the same period relative to her reproductive timeline.

Depo-Provera long-term use and cumulative hormonal exposure risk infographic showing how years of medroxyprogesterone acetate MPA exposure correlates with increasing meningioma brain tumor risk
Cumulative MPA exposure is the key risk variable — earlier first use means more total lifetime exposure, and higher meningioma risk
Started at 16

If continued to age 30: 14 years of exposure — approximately 56 injections, highest cumulative hormonal dose of any user cohort

Started at 22

If continued to age 30: 8 years of exposure — still significant, but 43% lower total dose than someone who started at 16

Started at 30

If continued to age 38: 8 years of exposure — same duration, but starting later means fewer total years of hormonal influence during formative adult brain development

The 2021 French epidemiological study that underpins much of the current litigation found that the meningioma risk was particularly concentrated in users with the highest cumulative progestin dose — a category that disproportionately includes women who began in their teens.

Why So Many Teenage Girls Were Prescribed Depo-Provera

Depo-Provera was not prescribed to teenage girls despite its convenience — it was prescribed because of it. Four injections per year, administered by a physician, with no daily compliance requirement, made it an attractive recommendation for young patients. The uses were wide-ranging:

vaccines
Contraception

The most common reason. Marketed as over 99% effective with no daily pill to forget. Widely prescribed to sexually active teenagers as a "set it and forget it" contraceptive option.

medical_services
Endometriosis Management

Girls diagnosed with endometriosis as young as 14 were routinely prescribed Depo-Provera to suppress menstruation and reduce pelvic pain — often continuing for many years.

healing
PCOS and Irregular Periods

Polycystic ovary syndrome often presents in adolescence. Depo-Provera was frequently used off-label to regulate hormonal symptoms, suppress ovulation, and reduce androgen levels.

bloodtype
Heavy Menstrual Bleeding

Girls with menorrhagia (abnormally heavy periods) were prescribed Depo-Provera to suppress periods entirely — sometimes during middle and high school years, well before the full brain tumor risk was publicly disclosed.

warning
The warning came decades too late

The FDA did not require Pfizer to add a meningioma brain tumor warning to Depo-Provera's label until February 2024. The girls prescribed this medication in the 1990s, 2000s, and 2010s had no access to that warning — and neither did their parents or doctors.

Symptoms Young Women Should Watch For

Meningiomas often grow slowly and can be present for years before causing noticeable symptoms. Young women who used Depo-Provera for extended periods should be aware of the following warning signs — especially if symptoms are persistent or progressively worsening:

psychology
Persistent headaches
Especially morning or pressure-type
visibility
Vision changes
Blurring, double vision, peripheral loss
hearing
Hearing loss or tinnitus
One-sided ringing or hearing reduction
accessible_forward
Balance problems
Dizziness, coordination changes
face
Facial numbness
Tingling or weakness on one side
memory
Memory or cognitive changes
Unexplained concentration difficulty

If you or your daughter used Depo-Provera for more than one year — especially starting in the teenage years — and are experiencing any of these symptoms, speak with your physician about an MRI evaluation. Early detection of meningioma is associated with significantly better outcomes.

Legal Options for Young Women Affected by Depo-Provera

If you or your daughter used Depo-Provera — particularly starting in your teenage years — and were diagnosed with a meningioma, here is what you should know about your legal options:

Claims against Pfizer — no need to prove doctor negligence

Product liability claims against Pfizer focus on the company's failure to adequately warn about the meningioma risk — not on what your individual doctor did or said. You do not need to prove your physician acted wrongly to pursue a claim against the manufacturer.

Early age of first use may strengthen your case

Plaintiffs who started Depo-Provera in their teens can demonstrate unusually high cumulative exposure — which directly corresponds to elevated meningioma risk. This can support both causation arguments and damages claims related to the length and severity of harm.

Minor at first prescription — additional protections may apply

If you were under 18 when first prescribed Depo-Provera, additional legal considerations apply — including enhanced informed consent requirements for minors and, in some states, extended statutes of limitations that run from the age of majority rather than the date of injury.

Related Depo-Provera Guides

Frequently Asked Questions

Can Depo-Provera cause brain tumors in young women who started as teenagers?expand_more
Yes. Research shows meningioma risk is linked to cumulative MPA exposure — the active ingredient in Depo-Provera. Women who began using Depo-Provera in their teens and continued for years accumulate the highest lifetime hormonal exposure and therefore face the greatest documented meningioma risk. A 2021 French study found a 5.6x elevated meningioma risk among long-term high-dose progestin users.
Why was Depo-Provera prescribed to teenage girls?expand_more
Depo-Provera was commonly prescribed to teenage girls for contraception, endometriosis, PCOS, and heavy periods. It was marketed as convenient — quarterly injections rather than a daily pill. The meningioma risk was not disclosed to most patients or their families at the time of prescribing, and no warning appeared on the drug's label until February 2024.
My daughter was prescribed Depo-Provera as a teen and now has a meningioma — do we have a case?expand_more
Potentially yes, and the early age of first use may strengthen the case by demonstrating unusually high cumulative exposure. You should consult a Depo-Provera attorney promptly. Claims can be brought against Pfizer and potentially your prescribing physician. Most attorneys handle these cases on contingency — no upfront fees, no fees unless you win.
Does age of first Depo-Provera use affect lawsuit eligibility?expand_more
It does not disqualify you — and in many ways strengthens your case. Earlier first use means longer potential exposure and higher total cumulative MPA dose. For women who were minors when first prescribed, there may also be extended statutes of limitations that run from the age of majority rather than the injury date.
How long after stopping Depo-Provera does the meningioma risk remain elevated?expand_more
Research suggests the elevated risk decreases after stopping but may remain elevated for several years, particularly in women who used Depo-Provera for extended periods. Women who stopped years ago but have persistent neurological symptoms should still seek MRI evaluation and legal consultation — the discovery rule may extend your filing window.
Free, Confidential Consultation

You Were Young. You Trusted a Prescription. You Deserved Better.

If you were prescribed Depo-Provera as a teenager and have since been diagnosed with a meningioma, the law may be on your side. Get a free, confidential case review from an experienced Depo-Provera attorney.

gavel Get a Free Case Evaluation

No fees unless we win. Available 24/7. Your privacy is protected.